Imputation of TPMT defective alleles for the identification of patients with high-risk phenotypes by Berta Almoguera et al.
ORIGINAL RESEARCH ARTICLE
published: 12 May 2014
doi: 10.3389/fgene.2014.00096
Imputation of TPMT defective alleles for the identification
of patients with high-risk phenotypes
Berta Almoguera1*, Lyam Vazquez1, John J. Connolly1, Jonathan Bradfield1, Patrick Sleiman1,2,
Brendan Keating1,2 and Hakon Hakonarson1,2
1 Center for Applied Genomics, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA
2 Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
Edited by:
Helena Kuivaniemi, Geisinger Health
System, USA
Reviewed by:
Peter A. Kanetsky, Moffitt Cancer
Center, USA
Kelli K. Ryckman, University of Iowa,
USA
*Correspondence:
Berta Almoguera, Center for Applied
Genomics, The Children’s Hospital
of Philadelphia, 3615 Civic Center
Boulevard, Abramson Building,
Philadelphia, PA 19104, USA
e-mail: castillob@email.chop.edu
Background: The activity of thiopurine methyltransferase (TPMT) is subject to
genetic variation. Loss-of-function alleles are associated with various degrees of
myelosuppression after treatment with thiopurine drugs, thus genotype-based dosing
recommendations currently exist. The aim of this study was to evaluate the potential utility
of leveraging genomic data from large biorepositories in the identification of individuals
with TPMT defective alleles.
Material and methods: TPMT variants were imputed using the 1000 Genomes Project
reference panel in 87,979 samples from the biobank at The Children’s Hospital of
Philadelphia. Population ancestry was determined by principal component analysis using
HapMap3 samples as reference. Frequencies of the TPMT imputed alleles, genotypes and
the associated phenotype were determined across the different populations. A sample of
630 subjects with genotype data from Sanger sequencing (N = 59) and direct genotyping
(N = 583) (12 samples overlapping in the two groups) was used to check the concordance
between the imputed and observed genotypes, as well as the sensitivity, specificity and
positive and negative predictive values of the imputation.
Results: Two SNPs (rs1800460 and rs1142345) that represent three TPMT alleles (∗3A,
∗3B, and ∗3C) were imputed with adequate quality. Frequency for the associated enzyme
activity varied across populations and 89.36–94.58% were predicted to have normal
TPMT activity, 5.3–10.31% intermediate and 0.12–0.34% poor activities. Overall, 98.88%
of individuals (623/630) were correctly imputed into carrying no risk alleles (553/553),
heterozygous (45/46) and homozygous (25/31). Sensitivity, specificity and predictive
values of imputation were over 90% in all cases except for the sensitivity of imputing
homozygous subjects that was 80.64%.
Conclusion: Imputation of TPMT alleles from existing genomic data can be used as a first
step in the screening of individuals at risk of developing serious adverse events secondary
to thiopurine drugs.
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INTRODUCTION
Thiopurine S-methyltransferase (TPMT) is an enzyme involved
in the metabolism of purine analogs such as azathioprine,
6-mercaptopurine and thioguanine, drugs that are used as
chemotherapeutic and immunosuppressant agents in diseases
such as lymphoid malignancies, leukemias, inflammatory bowel
disease, and other immune conditions (Relling et al., 2011;
Appell et al., 2013). TPMT maps to chromosome 6p22.3. It
is subject to genetic variation and, to date, 34 alleles have
been identified and characterized, most of which are associated
with reduced activity in vitro (Relling et al., 2011). Alleles ∗2
(rs1800462), ∗3A (rs1800460 and rs1142345), ∗3B (rs1800460),
and ∗3C (rs1142345) account for 95% of all defective alle-
les and all four involve missense mutations: allele ∗2 results
in the p.Ala80Pro change (chr6:18143955), allele ∗3A con-
tains two missense changes: p.Ala154Thr (chr6: 6:18139228)
and p.Tyr240Cys (chr6:18130918), and alleles ∗3B and ∗3C are
defined by p.Ala154Thr and p.Tyr240Cys, respectively (refer-
ence sequence NP_000358.1). The frequencies of these alleles
vary significantly across ethnic populations (Appell et al., 2013):
while ∗3A is the most frequently found in Caucasians (4.5%)
(Schaeffeler et al., 2004), ∗3C is more prevalent in Africans or
Asians, with 5.4–7.6% and 0.3–3%, respectively (reviewed in Teml
et al., 2007).
TPMT enzymatic activity exhibits a trimodal distribution
and approximately 0.3% of the population carry two defec-
tive alleles (associated with negligible activity), about 10% are
heterozygous (intermediate activity), and 89% have normal activ-
ity (Weinshilboum and Sladek, 1980; Schaeffeler et al., 2004).
Therefore, both heterozygous and homozygous individuals are at
higher risk of developing myelosuppression within a few weeks
after starting treatment with conventional doses that can be lethal
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if unrecognized, independent of the underlying disease being
treated (Sim et al., 2013).
Due to the potential cytotoxicity and narrow therapeutic index
of thiopurines, the US Food and Drug Administration (FDA)
recommends TPMT testing prior to starting treatment with
thiopurine drugs, and TPMT genotype-guided dosing recom-
mendations are currently in use (Relling et al., 2011, 2013).
Results of genetic tests are potentially relevant over a patient’s
lifetime and having that information incorporated into patients’
medical records may be useful in the improvement and guid-
ance of drug treatments, if ever needed. With electronic medical
records (EMR) currently widely implemented at academic hos-
pitals and other treatment institutions, pharmacogenetic action-
able variants can be integrated to the already available patient’s
information, helping optimize clinical decision making and care
planning (Gottesman et al., 2013). Moreover, genome-wide data
is increasingly accessible due to decreasing costs of genomic
technologies and the development of methods that allow for
accurate imputation of genotypes not directly probed by spe-
cific arrays could influence health care decisions (Marchini and
Howie, 2010). Genomic data is frequently stored within large
biorepositories where DNA samples are linked with phenotypic
data. These biorepositories have been efficient and successful
in studies of genotype-phenotype associations and they can be
used as a model for the implementation and evaluation of phar-
macogenomics in routine clinical practice (Gottesman et al.,
2013).
In the present study, we leverage existing genome-wide geno-
typing data to impute common defective TPMT alleles with the
aim of identifying individuals carrying high-risk genotypes for
thiopurines-induced adverse events.
MATERIAL AND METHODS
SUBJECTS AND GENOTYPING
This study was approved by the institutional review board and
the ethics committee of The Children’s Hospital of Philadelphia
(CHOP). Written informed consent was obtained from each
participant in accordance with institutional requirements and
the Declaration of Helsinki Principles. Subjects were selected
from the biorepository at the Center for Applied Genomics
at CHOP. The CHOP biobank has a collection of over
160,000 samples including 60,000 internal pediatric samples
and over 100,000 adult and pediatric samples from exter-
nal collaborators genotyped using standard GWAS arrays from
Illumina and Affymetrix (summarized in Gottesman et al.,
2013).
Figure 1 illustrates the study process. For TPMT imputation,
we selected a total of 87,979 samples genotyped with either
InfiniumII HumanHap550 (550; N = 45,893) or Human610-
Quad version 1 (Quad; N = 42,086) arrays (Illumina, San
Diego, CA). Genotyping data were used to impute sex using
PLINK (http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell
et al., 2007); population ancestry was determined by princi-
pal component analysis (Eigenstrat 3.0) (Price et al., 2006), and
samples were grouped into populations using nearest neighbors
analysis and the HapMap3 samples (https://www.sanger.ac.uk/
resources/downloads/human/hapmap3.html) as a reference.
IMPUTATION OF TPMT GENOTYPES
Imputation of unobserved genotypes in TPMT gene locus
(chr6:18,128,545–18,155,374) was carried out with the IMPUTE2
package (http://mathgen.stats.ox.ac.uk/impute/impute_v2.html)
(Howie et al., 2009) with the 1,000 Genomes Project reference
panel, after prephasing chromosome 6 haplotypes with SHAPEIT
version 2 (http://www.shapeit.fr/) (Delaneau et al., 2013). Since
rs1800460 is probed on the IlluminaHH610Quad array, prephas-
ing and imputation was performed for each chip type separately.
Quality control filters were applied and only SNPs with an info
score>0.9 were kept.
VALIDATION OF THE IMPUTED GENOTYPES
To determine the accuracy of imputation, TPMT imputed hap-
lotypes were compared to those obtained by other genotyping
platforms covering TPMT variation. Of the 87,979 samples, 583
also had genotyping data on Illumina Infinium Immunochip
(Immunochip), and HumanOmni1-Quad version 1 (Omni),
which captured both rs1800460 and rs1142345. Additionally,
Sanger sequencing of rs1800460 in exon 7 and rs1142345 in exon
10 was used to validate the imputation results (primers previ-
ously described in Schaeffeler et al., 2001). The sample selected for
Sanger sequencing consisted of 59 individuals predicted to carry
one or two defective alleles by imputation that had been exposed
to a TPMT medication based on the EMR.
DETERMINATION OF THE CONCORDANCE AND THE SENSITIVITY,
SPECIFICITY, POSITIVE AND NEGATIVE PREDICTIVE VALUES OF THE
IMPUTATION FOR THE IDENTIFICATION OF CARRIERS OF TPMT
DEFECTIVE ALLELES
We determined the concordance of the imputation as the number
of imputed genotypes that correspond with output from direct
genotyping or sequencing (expressed as percentage). Sensitivity,
specificity and positive and negative predictive values of the
imputation in the discrimination of subjects carrying the ∗1/∗1
genotype, and one and two TPMT defective alleles were deter-
mined as shown in Figure 2.
RESULTS
SUBJECTS AND TPMT IMPUTATION
Ancestry, sex estimation and imputation of TPMT genotypes
for the 89,797 individuals were performed in eleven batches
of ∼8,000 samples. An average of 174,911 SNPs with r2 < 0.2
were used for principal components calculation.
There were 50.04% males out of the 89,797 individuals
(imputed sex for 0.87% of the individuals was undetermined).
Principal component analysis classified 72.74% of individuals as
Caucasians, 18.78% with African ancestry, 6.55% Hispanics, and
1.93% Asians (Table 1). There were also data on self-reported
ethnicity for 24,527 out of the 89,797 individuals, with 50.15%
Caucasians (N = 12,304), 41.81% African Americans (N =
10,263), 1.6% Asians (N = 385), 0.08% American Indians (N =
21), 0.03% Native Hawaiians (N = 7), 0.02% Indians (N = 5),
and 6.29%were considered as “Other” (N = 1542). Concordance
between self-reported and imputed ancestry was >80% for
Caucasians, African Americans, and Asians (93.92, 98.34, and
81.30%, respectively). For the remaining groups, 57.58% were
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CHOP Biobank (N=87,979) 
Hap550: N=45,893  
Quad: N=42,086  
Imputation 
SHAPEIT 
IMPUTE2 
QC: info > 0.9 
Known functional consequence 
Imputation of sex 
(PLINK) and ancestry 
(EIGENSTRAT) 
Determination of the TPMT haplotype 
TPMT*1 rs1800460C/rs1142345T 
TPMT*3A: rs1800460T/rs1142345C 
TPMT*3B: rs1800460T/rs1142345T 
TPMT*3C: rs1800460C/rs1142345C 
Validation of the accuracy of the imputation 
Concordance 
Sensitivity 
Specificity 
Positive predictive value 
Negative predictive value 
Sanger sequencing 
59 individuals with 1 (N=28) or 2 
alleles (N=31) 
Genotyping 
583 individuals genotyped with 
Immunochip and Omni 
FIGURE 1 | General schema for the study process. Hap550 is the InfiniumII HumanHap550 array, Quad is Human610-Quad version 1 array, Immunochip is
the Illumina Infinium Immunochip array and Omni is the HumanOmni1-Quad version 1.
FIGURE 2 | Definition of true and false positive and negative values and formulae used for the determination of the sensitivity, specificity, and
predictive values of the imputation.
classified as Hispanics (19 out of 33), 15.15% as Asians (N =
5) and Caucasians (N = 5) and 12.12% as African Americans
(N = 4).
Three hundred and fifty four variants were imputed in the
TPMT gene, including 322 SNPs and 33 insertion/deletion
polymorphisms (indels). Out of these, only 117 had an info
value ≥0.9 (103 SNPs and 14 indels). However for the subse-
quent analysis only those with a known functional significance
were considered: rs1800460 and rs1142345, which define alleles
∗3A, ∗3B, and ∗3C. The loss-of-function variant rs1800462 that
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Table 1 | Frequencies of the different ethnicities in the sample
investigated based on principal component analysis of imputed
genotype data.
Population N (%)
Caucasians 63,998 72.74
CEU, Utah residents with
ancestry from northern and
western Europe
56,675 64.42
TSI, Toscans in Italy 7,323 8.32
African ancestry 16,519 18.78
ASW, African ancestry in
Southwest USA
15,457 17.57
YRI, Yoruba in Ibadan, Nigeria 947 1.08
MKK, Maasai in Kinyawa, Kenya 96 0.11
LWK, Luhya in Webuye, Kenya 19 0.02
Hispanics 5,764 6.55
MEX, Mexican ancestry in Los
Angeles, California
4,786 5.44
GIH, Gujarati Indians in Houston,
Texas
978 1.10
Asians 1,698 1.93
CHD, Chinese in Metropolitan
Denver, Colorado
1,043 1.19
JPT, Japanese in Tokyo, Japan 269 0.91
CHB, Han Chinese in Beijing,
China
386 0.43
defines allele ∗2 was also imputed but did not pass the quality
filters, thus it was excluded from the further analyses.
TPMT alleles were assigned as ∗1 when the rs1800460
C>T/rs1142345 T>C diplotype was CT, ∗3B when TT, and ∗3C
when CC. For allele ∗3A, given the high linkage disequilibrium
between rs1800460 (∗3B) and rs1142345 (∗3C) and the lowminor
allele frequency, whenever an individual carried both variants
(rs1800460T and rs1142345C), the allele was assigned as ∗3A.
TPMT allelic, genotypic and associated phenotypic frequen-
cies for ∗3A, ∗3B, and ∗3C across ethnic groups are illustrated in
Tables 2, 3 and 4, respectively. As shown in Table 2, the distribu-
tion of the three defective alleles varied largely across populations:
∗3A was more represented among the Caucasians, ∗3B in the
Hispanics and ∗3C in both Asians and African Americans, being
the latter the group with the highest frequency of carriers of
TPMT defective alleles (5.49 vs. 4.07% in Caucasians, 4.41%
in Hispanics and 2.77% in Asians). According to the genotype-
associated enzymatic activity, Asians harbored the lowest rates of
poor metabolizers with only 0.12% whereas Caucasians, African
Americans and Hispanics have a frequency close to 0.33%.
CONCORDANCE, SENSITIVITY, SPECIFICITY, AND POSITIVE AND
NEGATIVE PREDICTIVE VALUES OF THE IMPUTATION
Out of the 87,979 samples used for imputation, 583 had geno-
typing data on both rs1800460 and rs1142345: 94.8% of them
carried the genotype ∗1/∗1, 4.5% ∗1/∗3A, and 0.7% the geno-
type ∗1/∗3C. Concordance of the imputed haplotypes compared
to those determined by genotyping was 99.8% (Table 5).
Sanger sequencing was performed in a subset of 59 samples
predicted to carry 1 (N = 28) or 2 (N = 31) defective alleles
(∗3A, or ∗3C). Twelve of the 59 samples also had genotype data
and results were consistent across the two methods and with
the imputation. The overall concordance was 84.7% for the total
59 samples. Table 6 illustrates the concordance of the imputed
genotypes after validation with Sanger sequencing.
When taking into account the number of defective alleles,
98.88% of individuals (623 of the 630 individuals—excluding the
12 in the two groups-) were accurately imputed. All of the sam-
ples identified as carrying no risk alleles (∗1/∗1) were confirmed
by direct genotyping or sequencing (553/553) and for heterozy-
gous and homozygous individuals, the concordance was lower,
with 97.8% (45/46) and 80.64% (25/31), respectively (Table 7).
Sensitivity, specificity and positive and negative predictive values
of imputation of TPMT genotypes are summarized in Table 7.
Since the importance of TPMT genotyping lies in the discrim-
ination of individuals carrying defective alleles, these metrics
were determined for the discrimination of individuals carrying
the ∗1/∗1 genotype, individuals with one defective allele and
individuals with two defective alleles. Sensitivity, specificity, and
predictive values were close to 100% for all cases except for
the positive predictive value of identifying homozygous carriers,
which was 80.64%.
DISCUSSION
A growing number of drug-gene interactions, affecting rou-
tinely prescribed drugs, are being validated (Relling and Klein,
2011). The FDA has to date recommended the inclusion of
pharmacogenetic markers in the labels of more than a 100
drugs (http://www.fda.gov/drugs/scienceresearch/researchareas/
pharmacogenetics/ucm083378.htm) (Shuldiner et al., 2013)
and initiatives such as Pharmacogenomics Knowledge Base
(PharmGKB) and the Clinical Pharmacogenetics Implementation
Consortium (CPIC) (Relling and Klein, 2011) provide essential
pharmacogenetic information and play a major role in establish-
ing recommendations to aid clinicians in guiding therapies. If
one considers the report by Schildcrout et al, who demonstrated
that up to 65% of patients were exposed to at least one medi-
cation with an established drug-gene association within 5 years
(Schildcrout et al., 2012), then pharmacogenetics integration
into individuals’ medical records for clinical use is becoming an
urgent need. Availability of pharmacogenetic information prior
to patients’ treatment has the opportunity to identify individuals
potentially benefiting from a given therapy, select adequate med-
ications and doses, in order to ultimately administer the most
effective treatment to each patient, with the lower incidence of
adverse events.
Using existing genomic data from the CHOP biobank repos-
itory we have been able to impute three of the most common
defective TPMT alleles ∗3A, ∗3B, ∗3C in a cohort of 87,979
individuals. The sensitivity, specificity and positive and nega-
tive predictive values of the imputation were sufficiently high to
allow discrimination of patients carrying one or two defective
alleles from those with a ∗1/∗1 genotype. Concordance between
observed and imputed genotypes was 100% for individuals with
∗1/∗1 genotype, and for carriers of TPMT alleles, discordant
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Table 2 | Distribution of allele frequencies for TPMT alleles *3A, *3B, and *3C across the different ethnic groups.
Caucasian AA Hispanic Asian Total
(N = 63,998) (N = 16,519) (N = 5,764) (N = 1,698) (N = 87,979)
Allele N (%) N (%) N (%) N N (%)
*1 122,787 (95.93) 31,225 (94.51) 11,020 (95.59) 3,302 (97.23) 168,333 (95.67)
*3A 4,305 (3.36) 303 (0.92) 334 (2.90) 19 (0.56) 4,961 (2.82)
*3B 86 (0.07) 1 (0.00) 12 (0.10) 0 (0.00) 99 (0.06)
*3C 817 (0.64) 1,509 (4.57) 162 (1.41) 75 (2.21) 2,563 (1.46)
Table 3 | Distribution of genotypes for TPMT alleles *3A, *3B, and *3C across the different ethnic groups.
Caucasian AA Hispanic Asian Total
(N = 63,998) (N = 16,519) (N = 5,764) (N = 1,698) (N = 87,979)
Genotype N (%) N (%) N (%) N (%) N (%)
*1/*1 58,981 (92.16) 14,761 (89.36) 5,275 (91.52) 1,606 (94.58) 80,623 (91.64)
*1/*3A 4,119 (6.44) 286 (1.73) 322 (5.59) 19 (1.12) 4,746 (5.39)
*1/*3B 10 (0.02) 1 (0.01) 1 (0.02) 0 (0.00) 12 (0.01)
*1/*3C 697 (1.09) 1,416 (8.57) 147 (2.55) 71 (4.18) 2,331 (2.65)
*3A/*3A 81 (0.13) 1 (0.01) 5 (0.09) 0 (0.00) 87 (0.10)
*3A/*3B 1 (0.01) 0 (0.00) 0 (0.00) 0 (0.00) 1 (0.001)
*3A/*3C 23 (0.04) 15 (0.09) 2 (0.03) 0 (0.00) 40 (0.05)
*3B/*3C 75 (0.12) 0 (0.00) 11 (0.19) 0 (0.00) 86 (0.10)
*3C/*3C 11(0.02) 39 (0.24) 1 (0.02) 2 (0.12) 53 (0.06)
Table 4 | TPMT genotype-associated phenotypic frequencies across the different ethnic groups.
Caucasian AA Hispanic Asian Total
(N = 63,998) (N = 16,519) (N = 5,764) (N = 1,698) (N = 87,979)
TPMT activity N (%) N (%) N (%) N (%) N (%)
Normal 58,981 (92.16) 14,761 (89.36) 5,275 (91.52) 1,606 (94.58) 80,623 (91.64)
Intermediate 4,826 (7.54) 1,703 (10.31) 470 (8.15) 90 (5.30) 7,089 (8.06)
Low 191 (0.30) 55 (0.33) 19 (0.33) 2 (0.12) 267 (0.30)
results were essentially cases of individuals predicted to be het-
erozygous by imputation that were found to be homozygous by
genotyping or sequencing. Additionally, probably because of the
rarity of SNPs rs1800460 and rs1142345 and the increase in impu-
tation errors as minor allele frequency decreases, alleles ∗3A and
∗3C were frequently switched, and allele ∗3B was only identified
in the subset of samples genotyped with the Quad array. The rar-
ity of allele ∗2 may also be the explanation for the inability of
imputing with adequate quality.
TPMT deficiency exhibits an extensive interethnic variability
(Wang et al., 2010; Appell et al., 2013). The population inves-
tigated in this study is characterized for being largely admixed
with African Americans, Asians and Hispanics accounting for
almost 30% of all individuals. As previously described, frequency
of alleles ∗3A, ∗3B and ∗3C is population-specific. Whereas ∗3A
and ∗3B were predominantly found in Caucasians and Hispanics
(3.36 and 2.90%, for ∗3A and 0.07 and 0.1%, for ∗3B, respec-
tively), the most prevalent defective allele in African Americans
Table 5 | Concordance between the imputed genotypes and
genotypes determined by genotyping using Immunochip (Illumina
Infinium Immunochip array) and Omni (HumanOmni1-Quad version
1) (N = 583).
Imputation Genotyping
*1/*1 *1/*3A *1/*3C Total
*1/*1 553 0 0 553
*1/*3A 0 26 0 26
*1/*3C 1 0 3 4
Total 554 26 3 583
and Asians was ∗3C (4.57 and 2.21%, respectively). These results
were similar to frequencies previously reported for those pop-
ulations (Oliveira et al., 2007; Taja-Chayeb et al., 2008; Appell
et al., 2013). Regarding TPMT associated-phenotypes, African
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Americans had the highest proportion of intermediate (10.31%)
and low methylators (0.33%), being the ethnic group with the
highest risk of developing adverse events derived from TPMT
treatment. Conversely, Asians are the lowest risk group, with only
5.4% of individuals carrying one (5.30%) or two alleles (0.12%).
Caucasians and Hispanics had a similar percentage of individuals
with TPMT intermediate (7.54 and 8.15%, respectively) and low
activity (0.30 and 0.33%, respectively). Other population-specific
alleles not imputed in the current study, such as ∗2 that is almost
restricted to Caucasians, or ∗6 (rs75543815) and ∗8 (rs56161402)
that occur at frequencies between 1.5 and 3.5% in some African
and Asian populations (Oliveira et al., 2007), are also impor-
tant contributors of TPMT deficiency. These rare TPMT alleles
or novel variants will not be detected with this approach and can
only be identified by direct genotyping or sequencing. Thus, the
frequency of intermediate and low methylators in this study may
be slightly underestimated.
It is worth mentioning that approximately 1 in 10 individ-
uals tested from our biobank were found to carry at least one
high-risk TPMT allele. There are currently over 2.5 million
children enrolled in the CHOP healthcare system, and if one
extrapolates the results yielded from this study to the entire pop-
ulation at CHOP, then more than 170,000 patients would be
expected to be TPMT deficient. Identification of such carriers
is especially important in the pediatric population, as thiop-
urines are commonly prescribed drugs in children. Thiopurines
are the backbone drugs for maintenance of acute lymphoblastic
leukemia (ALL), which is the most common childhood malig-
nancy (Pui and Evans, 2006), and are also frequently used as
Table 6 | Concordance between imputed genotypes and genotypes
determined by Sanger sequencing (N = 59).
Imputation Sanger sequencing
*1/*1 *1/*3A *1/*3C *3A/*3A *3A/*3C *3C/*3C Total
*1/*1 0 0 0 0 0 0 0
*1/*3A 0 19 0 0 0 0 19
*1/*3C 0 0 9 0 0 0 9
*3A/*3A 1 0 0 6 0 0 7
*3A/*3C 0 0 1 0 3 1 5
*3C/*3C 0 0 4 1 1 13 19
Total 1 19 14 7 4 14 59
chronic immunosuppressive therapy after organ transplantation
and in inflammatory bowel disease (Dubinsky, 2004; Relling
et al., 2011; Appell et al., 2013). A major limitation of their
use is their narrow therapeutic index and the severe myelosup-
pression they cause, a life threating adverse event highly asso-
ciated with TPMT deficiency (Relling et al., 1999). In a study
by Relling and coworkers in 180 children with ALL receiving
conventional doses of 6-mercaptopurin, the authors found that
the cumulative incidence of toxicity was 100% for homozy-
gous TPMT deficiency, 35% for heterozygous, and 7% for
patients homozygous for allele ∗1 (Relling et al., 1999). This
association has been widely replicated, so genotyping of TPMT
is recommended in US FDA-approved labeling and currently
genotype-based dosing recommendations exist (Relling et al.,
2011, 2013). The high genotype-phenotype correlation existent
for TPMT and the large interethnic variability in the suscepti-
bility to thiopurine hematopoietic toxicity, sustain the need of
availing such genetic information to prospectively identify indi-
viduals where thiopurine therapy may need to be modified or
changed.
Biorepositories where DNA samples are linked to the EMR
of patients, such as the CHOP biobank, offer the ideal
platform for screening and identification of individuals with
high-risk genotypes that may require a modification in the
therapy if a given drug is prescribed. CHOP is part of the
Electronic Medical Records and Genomics (eMERGE) con-
sortium that is actively working on large-scale testing and
integration of information on actionable pharmacogenetic vari-
ants, such as TPMT alleles, into clinical practice using EMR
technologies (Gottesman et al., 2013). One of the goals of
eMERGE is the creation of SPHINX (Sequence, Phenotype,
and pHarmacogenomics INtegration eXchange http://www.
emergesphinx.org/), a web accessible repository of genomic
variants derived from a panel of 84 genes involved in the
pharmacogenetics of a large number of drugs, designed by the
NIH-supported Pharmacogenetics Research Network (PGRN),
and linked to clinical information. To date, SPHINX contains
data on 2000 of the nearly 9000 subjects that are planned to
be enrolled in the project. Interestingly, so far SPHINX lists
174 variants in the TPMT gene, including known and novel
variants, and the minor allele frequency information. Variant
repositories such as SPHINX allow the advance in the knowledge
of pharmacogenetics through the exploration of new hypothe-
ses and the further integration of this information into the
EMR.
Table 7 | Concordance between imputed and observed genotypes according to the number of defective alleles and characteristics of the
imputation in terms of sensitivity (S), specificity (SP), positive predictive value (PPV) and negative predictive value (NPV) (N = 630).
Observed genotypes Imputation metrics
Imputed genotypes 0 alleles 1 allele 2 alleles S SP PPV NPV
0 alleles 553 0 0 99.64 100 100 97.40
1 allele 1 45 0 90.00 99.83 97.82 99.14
2 alleles 1 5 25 100 99.01 80.64 100
Total 555 50 25
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The results yielded from this study demonstrate that imputa-
tion of TPMT alleles from existing genomic data is feasible and
may be used as a first step in the screening of high-risk individuals
for thiopurine drugs toxicity. Sensitivity, specificity, and predic-
tive values of the imputation were over 90% in all cases, except
for the positive predictive value of the imputation of homozygous
subjects. Given that around 90% of the population is expected to
have two fully functional TPMT alleles, being able to accurately
identify such individuals based on existing genomic data yields
10% of the population to be screened for high-risk genotypes
with direct genotyping methods. The positive and negative pre-
dictive values of 100 and 97.40%, respectively, obtained for the
discrimination of individuals with the ∗1/∗1 genotype supports
the potential utility of imputation in narrowing the target pop-
ulation where TPMT genotypes need to be determined. Further
integration of such pharmacogenetic information into the EMR,
with clinical decision support, may be used to aid clinicians pre-
scribe therapies with the maximum risk-benefit ratio based on
each individual’s information.
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